Biotech News
Related news
OCSOculis2026-05-29 19:06 EST
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
OCSOculis2026-06-09 08:00 EST
Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease
OKYOOKYO Pharma2026-09-09 11:00 EST
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
OCGNOcugen2026-09-01 11:02 EST
Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
OKYOOKYO Pharma2026-07-20 11:00 EST
OKYO Pharma Announces Filing of Annual Report with Strengthened Cash Position and Accelerated Phase 3 Plans
EYPTEyePoint Pharmaceuticals2026-05-14 11:00 EST
EyePoint Announces Third Consecutive Positive DSMC Recommendation for Phase 3 Wet AMD Trials for DURAVYU™, Building Confidence Ahead of Mid-2026 Topline Data
PRQRProQR Therapeutics2026-09-09 12:00 EST
ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026
EYPTEyePoint Pharmaceuticals2026-08-17 11:00 EST
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
BLTEBelite Bio2026-07-20 12:00 EST
Belite Bio Announces Oral Presentation at the ASRS Annual Meeting Featuring Additional Positive Secondary Endpoint Data from the Phase 3 Trial of Tinlarebant in Stargardt Disease Type 1
OCGNOcugen2026-10-06 11:02 EST
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European Affiliate
Oculis
Neuro-Ophthalmology Focus Oculis is a global biopharmaceutical company developing therapies for neuro-ophthalmic and ophthalmic diseases. Its strategy is centered on late-stage programs that protect visual function or apply a precision-medicine approach to ocular inflammation. Privosegtor Neuroprotection Privosegtor is a neuroprotective...
Recent company news
OCSOculis2026-10-07 06:00 EST
Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day
OCSOculis2026-10-01 06:00 EST
Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
OCSOculis2026-09-30 21:32 EST
Oculis Announces Resignation of Lionel Carnot from Board of Directors
OCSOculis2026-09-17 20:05 EST
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
OCSOculis2026-08-24 08:00 EST
First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
Stock data
- Close
- 8.72 USD
- Market cap
- 742.17M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States